



October 27, 2016

## **Sage Therapeutics to Report Third Quarter 2016 Financial Results on Thursday, November 3, 2016**

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday, November 3, 2016 at 8:00 am ET to report its third quarter 2016 financial results and discuss recent business updates.

The live webcast can be accessed on the investor page of Sage's website at [investor.sagerx.com](http://investor.sagerx.com). The conference call can be accessed by dialing 1-866-450-8683 (toll-free domestic) or 1-281-542-4847 (international) and using the conference ID 4543484. A replay of the webcast will be available on Sage's website approximately two hours after the completion of the event and will be archived for up to 30 days.

### **About Sage Therapeutics**

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and is being developed for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit [www.sagerx.com](http://www.sagerx.com).

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20161027006944/en/>

#### **Investor Contact:**

Sage Therapeutics  
Paul Cox, 617-299-8377  
[paul.cox@sagerx.com](mailto:paul.cox@sagerx.com)

or

#### **Media Contact:**

Suda Communications LLC  
Maureen L. Suda, 585-387-9248  
[maureen.suda@sagerx.com](mailto:maureen.suda@sagerx.com)

Source: Sage Therapeutics

News Provided by Acquire Media